Clinical Trials Browser

Phase 3 × NETWORK × Inotuzumab Ozogamicin × Clear all

NCT03959085 2026-03-31

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute